MedCannAccess cancelled the acqusition of Buccaneer Gold Corp in a reverse merger transaction.
On completion of the transaction, the management team and Board of Directors of the resulting issuer is expected to include the persons identified below: Blaine Dowdle, Director and Chief Executive Officer; Kevin Furet, Vice-President, Production; Rade Kovacevic, Vice-President, Business Development; Scott Belton, Quality Assurance Manager, Plant Research and Development Manager; Theresa Kozak, Client Services Manager and Paul Zyla, Director. A duly qualified Chief Financial Officer will be appointed prior to completion of the transaction. As on January 23, 2015, Buccaneer and MedCannAccess continue working towards completion of their transaction.
The transaction is subject to regulatory approval, including the approval of the TSX-V and standard closing conditions, including the approval of the transaction by the Directors of each of Buccaneer and MedCannAccess, completion of due diligence investigations to the satisfaction of each of the parties, negotiation and execution of a definitive agreement, receipt of all requisite approvals from shareholders of MedCannAccess and Buccaneer, third parties (including lenders or financial institutions, licensors and strategic partners involved in the manufacturing, distribution and sale of MedCannAccess' products) relating to the transaction. Buccaneer Gold, 8437726 Canada Inc. and Richmond Capital agreed to extend the due diligence period by 15 days in order to permit Buccaneer to have additional time to complete its studies. They have extended to September 15, 2014. The time for entering into definitive agreement is August 31, 2014.
MedCannAccess cancelled the acquisition of Buccaneer Gold Corp (TSXV:BGG) in a reverse merger transaction on May 26, 2015.